Display options
Cite
AbdulWahab A, Zahraldin K, Sid Ahmed MA, et al. The emergence of multidrug-resistant . Lung India. 2017;34(6):527-531doi: 10.4103/lungindia.lungindia_39_17.
AbdulWahab, A., Zahraldin, K., Sid Ahmed, M. A., Jarir, S. A., Muneer, M., Mohamed, S. F., Hamid, J. M., Hassan, A. A. I., & Ibrahim, E. B. (2017). The emergence of multidrug-resistant . Lung India : official organ of Indian Chest Society, 34(6), 527-531. https://doi.org/10.4103/lungindia.lungindia_39_17
AbdulWahab, Atqah, et al. "The emergence of multidrug-resistant ." Lung India : official organ of Indian Chest Society vol. 34,6 (2017): 527-531. doi: https://doi.org/10.4103/lungindia.lungindia_39_17
AbdulWahab A, Zahraldin K, Sid Ahmed MA, Jarir SA, Muneer M, Mohamed SF, Hamid JM, Hassan AAI, Ibrahim EB. The emergence of multidrug-resistant . Lung India. 2017 Nov-Dec;34(6):527-531. doi: 10.4103/lungindia.lungindia_39_17. PMID: 29098998; PMCID: PMC5684810.
Copy Download .nbib Format: NLM
Share it on

Lung India. 2017 Nov-Dec;34(6):527-531. doi: 10.4103/lungindia.lungindia_39_17.

The emergence of multidrug-resistant .

Lung India : official organ of Indian Chest Society

Atqah AbdulWahab, Khalid Zahraldin, Mazen A Sid Ahmed, Sulieman Abu Jarir, Mohammed Muneer, Shehab F Mohamed, Jemal M Hamid, Abubaker A I Hassan, Emad Bashir Ibrahim

Affiliations

  1. Department of Pediatrics, Hamad Medical Corporation; Weill Cornell Medicine, Qatar.
  2. Department of Pediatrics, Hamad Medical Corporation, Doha, Qatar.
  3. Department of Laboratory Medicine and Pathology, Microbiology Division, Hamad Medical Corporation, Doha, Qatar; The Life Science Centre - Biology, School of Science and Technology, Örebro University, Örebro, Sweden.
  4. Department of Internal Medicine, Hamad Medical Corporation, Doha, Qatar.
  5. Plastic Surgery, Hamad Medical Corporation, Doha, Qatar.
  6. Department of Laboratory Medicine and Pathology, Microbiology Division, Hamad Medical Corporation, Doha, Qatar.
  7. Weill Cornell Medicine; Department of Laboratory Medicine and Pathology, Microbiology Division, Hamad Medical Corporation, Doha, Qatar.

PMID: 29098998 PMCID: PMC5684810 DOI: 10.4103/lungindia.lungindia_39_17

Abstract

INTRODUCTION: Multidrug-resistant Pseudomonas aeruginosa (MDR-PA) is an important and growing issue in the care of patients with cystic fibrosis (CF), and a major cause of morbidity and mortality.

OBJECTIVE: The objective of the study was to describe the frequency of MDR-PA recovered from the lower respiratory samples of pediatric and adult CF patients, and its antibiotic resistance pattern to commonly used antimicrobial agents including β-lactams, aminoglycosides, and fluoroquinolones.

MATERIALS AND METHODS: The lower respiratory isolates of P. aeruginosa were obtained from inpatients and outpatients CF clinics from a tertiary care teaching hospital for the period from October 2014 to September 2015. The identification and antimicrobial susceptibility for all the isolates were performed by using the BD Phoenix™ and E-test in compliance with Clinical and Laboratory Standards Institute (CLSI) guidelines.

RESULTS: A total of 61 P. aeruginosa samples were isolated from thirty CF patients from twenty families. Twelve sputum samples were positive for MDR-PA (seven nonmucoid and five mucoid isolates) from five CF patients (five families) with moderate-to-very severe lung disease given MDR-PA frequency of 19.7%. The median age of the study group was 20 (range 10-30) years. Three CF patients were on chronic inhaled tobramycin and two on nebulized colistin. The antimicrobial patterns of isolates MDR-PA showed the highest rate of resistance toward each gentamycin, amikacin, and cefepime (100%), followed by 91.7% to ciprofloxacin, 75% to tobramycin, 58.3% to meropenem, and 50% to piperacillin-tazobactam. None of the isolates were resistant to colistin during the study period.

CONCLUSION: The study results emphasize that the emergence of a significant problem in the clinical isolates of P. aeruginosa in CF patients that dictate appropriate attention to the antibiotic management after proper surveillance.

References

  1. J Cyst Fibros. 2012 Jul;11(4):293-9 - PubMed
  2. Cold Spring Harb Perspect Med. 2012 Sep 01;2(9):a009589 - PubMed
  3. Thorax. 2006 Feb;61(2):155-7 - PubMed
  4. Br Med Bull. 2009;89:93-110 - PubMed
  5. J Trop Pediatr. 2001 Apr;47(2):110-2 - PubMed
  6. Int J Med Microbiol. 2010 Dec;300(8):557-62 - PubMed
  7. JAMA. 2005 Feb 2;293(5):581-8 - PubMed
  8. Arch Pediatr Adolesc Med. 2011 Sep;165(9):847-56 - PubMed
  9. Thorax. 2014 Aug;69(8):740-5 - PubMed
  10. J Infect Dis. 2007 Jan 1;195(1):70-80 - PubMed
  11. J Cyst Fibros. 2015 Jan;14(1):111-9 - PubMed
  12. Am J Infect Control. 2004 Dec;32(8):470-85 - PubMed
  13. J Cyst Fibros. 2015 May;14(3):361-9 - PubMed
  14. Am J Clin Pathol. 2007 Jul;128(1):32-4 - PubMed
  15. Pediatr Pulmonol. 2013 Oct;48(10):943-53 - PubMed
  16. Am J Respir Crit Care Med. 2007 Nov 15;176(10):957-69 - PubMed
  17. Clin Infect Dis. 2002 Mar 1;34(5):634-40 - PubMed
  18. J Infect Dis. 2001 Feb 1;183(3):444-52 - PubMed
  19. Ann Am Thorac Soc. 2014 Dec;11(10):1640-50 - PubMed
  20. Braz J Infect Dis. 2012 Mar-Apr;16(2):122-8 - PubMed
  21. Semin Respir Crit Care Med. 2009 Oct;30(5):505-13 - PubMed
  22. Infect Drug Resist. 2014 Nov 20;7:309-16 - PubMed
  23. Paediatr Respir Rev. 2008 Jun;9(2):144-8 - PubMed
  24. Antimicrob Resist Infect Control. 2016 Feb 09;5:4 - PubMed
  25. Pediatr Pulmonol. 2001 Oct;32(4):277-87 - PubMed
  26. Nature. 2000 Oct 12;407(6805):762-4 - PubMed
  27. Respiration. 2006;73(1):27-33 - PubMed
  28. Am J Respir Crit Care Med. 2008 May 15;177(10):1058-61 - PubMed
  29. Thorax. 2010 Apr;65(4):286-91 - PubMed
  30. Saudi Med J. 2003 Jul;24(7):730-5 - PubMed
  31. Clin Microbiol Rev. 2011 Jan;24(1):29-70 - PubMed
  32. Science. 2000 May 19;288(5469):1251-4 - PubMed
  33. Clin Chest Med. 2012 Jun;33(2):307-28 - PubMed
  34. F1000Prime Rep. 2015 May 27;7:64 - PubMed

Publication Types